

<b>TRANSMITTAL SLIP</b>		<b>DATE</b> 4 May 83
<b>TO:</b> DDA		
<b>ROOM NO.</b> 7D24	<b>BUILDING</b> Hqrs	
<b>REMARKS:</b> <p>EO/ODA <i>[Signature]</i> 5 MAY 1983  A/ODA - FY1 <i>[Signature]</i> 5 MAY 1983  DDA - " <i>[Signature]</i> 6 MAY 1983</p>		
<b>FROM:</b> <input type="text"/>		
<b>ROOM NO.</b> 5F43	<b>BUILDING</b> Hqrs	<b>EXTENSION</b> <input type="text"/>

FORM NO. 241  
1 FEB 82

REPLACES FORM 36-8  
WHICH MAY BE USED

(47)

STAT

STAT

DD/A Registry  
83-1136/1

4 MAY 1983

DD/A REGISTRY  
FILE: 15-3

MEMORANDUM FOR: Chairman, Human Subjects Review Panel

FROM: Chairman, DCI/NIC CBW-Toxin Working Group

SUBJECT: Medical Screening Project [ ] 25X1

REFERENCE: Memorandum from [ ] 25X1  
dated 25 April 1983

1. Thank you for your continued advice per reference.  
I agree with your recommendations. [ ] 25X1

2. Accordingly, [ ] has relinquished 25X1  
the position as project medical director. The Medical  
Director of the Institute for Foreign Policy Analysis is  
[ ], M.D. Harvard Medical School, a specialist in 25X1  
tropical medicine with board certification in Internal  
Medicine. In addition to language capability in Thai,  
some Hmong, and Khmer he has had extensive appropriate  
in-country experience. [ ] 25X1  
25X1

[ ]  
Science and Technology Division/OSWR

SECRET


[ ] 25X1  
[ ]  
[ ]  
[ ]  
[ ]

SUBJECT: Medical Screening Project



25X1

Distribution:

- Orig - Addressee
- 1 - Executive Director
- 1 - Executive Registry
- 1 - OGC
- 1 - DDA
- 1 - D/OMS
- 1 - OSWR Chrono
- 1 - STD Chrono
- 1 - 


25X1

DDI/OSWR/STD



(4 May 1983)

25X1



25 April 1983

ED/A REGISTRY  
FILE: 15-3

MEMORANDUM FOR: Executive Director

FROM:

[Redacted]  
Chairman, Human Subjects Research Panel

SUBJECT: Protection of Human Subjects of Chemical/Toxin  
Weapons Screening Project

25X1

83-1136

1. This memorandum constitutes a progress report on the above-mentioned project. At the present time, it appears that the appropriate safeguards have been observed with respect to the protection of human subjects, except for the project medical director also being a member of the Institutional Review Board. Assurance from the Board that the medical director will not take part in the deliberations of the Board, except to provide information, would permit the Human Subjects Research Panel to certify that the project meets the Health and Human Services (HHS) guidelines.

2. Because of the time involved in this process, and since projects of this nature should be reviewed for compliance with the regulations in advance, the Panel will seek a meeting with you to discuss these and other problems shortly.

3. In March 1982, the Director of Central Intelligence requested [Redacted], STD/OSWR, to prepare a letter to Dr. Teller concerning the proposal for special relief to victims of chemical warfare in Thailand refugee war camps (Attachment A). The Executive Director was involved in this matter in August 1982 (Attachment B). The original proposal involved experimentation and treatment in addition to collection methods. The experimentation and treatment aspects have since been removed. The collection of human data, however, appears to constitute research under the HSS guidelines.

25X1

4. The Agency Human Subjects Research Panel has reviewed information provided by the Science and Technology Division, OSWR/DDS&T (Attachment C), concerning the Chemical-Biological Weapons Information Project conducted by the Institute for Foreign Policy Analysis, Inc., Cambridge, Massachusetts, in accordance with Part 2, paragraph 2.10 of Executive Order 12331 (4 December 1981) and

25X1

## Protection of Human Subjects of Chemical/Toxin Weapons Screening Project

Headquarters Regulation [redacted] (Attachment D). The Panel had made suggestions in this matter in November 1982 (Attachment E) so that the protection of human subjects would conform to the HHS guidelines as specified in the Executive Order and Headquarters Regulation. 25X1

5. From the documents submitted to the Panel, it appears that the HHS requirements for the protection of human subjects, as specified in the Code of Federal Regulations at 45 CFR 46 (revised 26 January 1981), have been observed. However, the Panel notes that [redacted] is listed as the project medical director, as well as a member of the Institutional Review Board. Because of his position with the project, [redacted] does not appear to be eligible for participation and deliberation in the Institutional Review Board's continuing monitoring of this project, except to provide information as requested. This is because of a seeming conflict of interest under HHS regulations [45 CFR 46.107(e)]. Since some Agency funding is involved, attention to this detail by the Institutional Review Board is necessary to provide the required protection for human subjects, whether examined in the United States or abroad. 25X1 25X1



### Attachments

OMS/PD/BMM:cmr/ext [redacted] (25 Apr 83) 25X1

### Distribution:

- 0 - Addressee w/atts
- 1 - OGC w/o atts
- 1 - DDA w/o atts
- 1 - D/MS w/o atts
- 1 - HSRP w/atts

Date

### ROUTING AND TRANSMITTAL S...


TO: (Name, office symbol, room number, building, Agency/Post)

1. <u>EO/DOA</u>	Initials	Date
2. <u>AOA</u>	<i>[Signature]</i>	18 APR 1963
3. <u>DOA</u>	<i>[Signature]</i>	20 APR 1963
4. _____		

Action	File	Note and Return
Approval	For Clearance	For Conversation
As Requested	For Correction	Prepare Reply
Circulate	For Your Information	See Me
Comment	Investigate	Signature
Coordination	Justify	

REMARKS

*1-2/3: This was revised at my request.*



STAT

DO NOT use this form as a RECORD of approvals, concurrences, disposals, clearances, and similar actions

FROM: (Name, org. symbol, Agency/Post)

Room No.—Bldg.

Phone No.

5041-102

☆ GPO : 1961 O - 361-529 (148)

OPTIONAL FORM 41 (Rev. 7-76)  
Prescribed by GSA  
FPMR (41 CFR) 101-11.205